| Rx0000356 |
Radius Health, Inc. |
03/31/2022 |
70539000101 |
TYMLOS 80 MCG Pen |
01/01/2022 |
167.62 |
2289.34 |
01/10/2040 |
Single Source Drug |
None |
1 |
Radius generally makes decisions on price revisions annually based on market conditions and corporate strategy, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients.
Radius takes into account several market and business considerations when setting a list price for a product, including, but not limited to:
- The clinical and health outcomes value of our products to patients and payors.
- Not only the budget impact to payers but also patient out of pocket costs to ensure that products reach the patients who need them.
- Responsible and competitive prices, in line with current treatment costs where other treatment options exist.
- Corporate business strategy, including costs and profitability.
- Consideration of other factors such as Annual CPI-U rates.
- R&D investment priorities and budgets to identify future medicines to improve the lives of patients
- Radius does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Radius believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 04/20/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Radius Health, Inc. did not acquire this product from another manufacturer within the previous five years. As a result, Radius Health has left columns N-U blank because they are not applicable to this product. |
| Rx0000356 |
Radius Health, Inc. |
03/31/2022 |
70539000102 |
TYMLOS 80 MCG Pen / Carton |
01/01/2022 |
167.62 |
2289.34 |
01/10/2040 |
Single Source Drug |
None |
1 |
Radius generally makes decisions on price revisions annually based on market conditions and corporate strategy, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients.
Radius takes into account several market and business considerations when setting a list price for a product, including, but not limited to:
- The clinical and health outcomes value of our products to patients and payors.
- Not only the budget impact to payers but also patient out of pocket costs to ensure that products reach the patients who need them.
- Responsible and competitive prices, in line with current treatment costs where other treatment options exist.
- Corporate business strategy, including costs and profitability.
- Consideration of other factors such as Annual CPI-U rates.
- R&D investment priorities and budgets to identify future medicines to improve the lives of patients
- Radius does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Radius believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 04/20/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Radius Health, Inc. did not acquire this product from another manufacturer within the previous five years. As a result, Radius Health has left columns N-U blank because they are not applicable to this product. |
| Rx0000363 |
Recordati Rare Diseases, inc. |
03/31/2022 |
55292020111 |
Chemet 100 mg (Succimer), 100 caps/bottle |
01/05/2022 |
164.88 |
2225.94 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
03/31/2022 |
55292081155 |
Cosmegen Inj 0.5 mg (Dactinomycin for Injection), 0.5 mg/vial |
01/05/2022 |
224.87 |
2473.55 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
03/31/2022 |
52276040001 |
Cystadane (betaine anhydrous for oral solution) powder, 180 gm/bottle |
01/05/2022 |
158.46 |
1826.43 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
03/31/2022 |
55292010401 |
Desoxyn 5 mg (Methamphetamine hydrochloride), 100 tab/bottle |
01/05/2022 |
187.19 |
2059.08 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
03/31/2022 |
55292032020 |
Isturisa (osilodrostat) 1 mg, 20 tablet |
01/05/2022 |
125.90 |
2643.80 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
03/31/2022 |
55292032060 |
Isturisa (osilodrostat) 1 mg, 60 tablet |
01/05/2022 |
377.69 |
7931.39 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
12/31/2022 |
55292032020 |
Isturisa Oral Tablet 1 MG Package Size 20 |
11/01/2022 |
251.16 |
2894.96 |
10/12/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/12/2019 |
Novartis |
0 |
1 |
None |
1.00 |
0.00 |
2020 |
2200.00 |
None |
The product was acquired from Novartis in the late stage development phase. It was brought to market the following year. As a result there was no WAC price at acquisition as the product was not on market at that time. We entered 1.00 for WAC at acquisition in order to submit the report. Recordati paid Novartis $390m for the acquisition of Signifor and in-development osilodrostat, which Recordati brought to market under the brand name Isturisa in 2020. |
| Rx0000363 |
Recordati Rare Diseases, inc. |
12/31/2022 |
55292032220 |
Isturisa Oral Tablet 10 MG Package Size 20 |
11/01/2022 |
1005.34 |
11587.82 |
10/12/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/12/2019 |
Novartis |
0 |
1 |
None |
1.00 |
0.00 |
2020 |
9500.00 |
None |
The product was acquired from Novartis in the late stage development phase. It was brought to market the following year. As a result there was no WAC price at acquisition as the product was not on market at that time. We entered 1.00 for WAC at acquisition in order to submit the report. Recordati paid Novartis $390m for the acquisition of Signifor and in-development osilodrostat, which Recordati brought to market under the brand name Isturisa in 2020. |
| Rx0000363 |
Recordati Rare Diseases, inc. |
12/31/2022 |
55292032260 |
Isturisa Oral Tablet 10MG Package Size 60 |
11/01/2022 |
3016.01 |
34763.44 |
10/12/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/12/2019 |
Novartis |
0 |
1 |
None |
1.00 |
0.00 |
2020 |
28500.00 |
None |
The product was acquired from Novartis in the late stage development phase. It was brought to market the following year. As a result there was no WAC price at acquisition as the product was not on market at that time. We entered 1.00 for WAC at acquisition in order to submit the report. Recordati paid Novartis $390m for the acquisition of Signifor and in-development osilodrostat, which Recordati brought to market under the brand name Isturisa in 2020. |
| Rx0000363 |
Recordati Rare Diseases, inc. |
12/31/2022 |
55292032060 |
Isturisa Oral Tablet 1MG Package Size 60 |
11/01/2022 |
753.48 |
8684.87 |
10/12/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/12/2019 |
Novartis |
0 |
1 |
None |
1.00 |
0.00 |
2020 |
6600.00 |
None |
The product was acquired from Novartis in the late stage development phase. It was brought to market the following year. As a result there was no WAC price at acquisition as the product was not on market at that time. We entered 1.00 for WAC at acquisition in order to submit the report. Recordati paid Novartis $390m for the acquisition of Signifor and in-development osilodrostat, which Recordati brought to market under the brand name Isturisa in 2020. |
| Rx0000363 |
Recordati Rare Diseases, inc. |
12/31/2022 |
55292032120 |
Isturisa Oral Tablet 5 MG Package Size 20 |
11/01/2022 |
846.60 |
9758.16 |
10/12/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/12/2019 |
Novartis |
0 |
1 |
None |
1.00 |
0.00 |
2020 |
8000.00 |
None |
The product was acquired from Novartis in the late stage development phase. It was brought to market the following year. As a result there was no WAC price at acquisition as the product was not on market at that time. We entered 1.00 for WAC at acquisition in order to submit the report. Recordati paid Novartis $390m for the acquisition of Signifor and in-development osilodrostat, which Recordati brought to market under the brand name Isturisa in 2020. |
| Rx0000363 |
Recordati Rare Diseases, inc. |
12/31/2022 |
55292032160 |
Isturisa Oral Tablet 5MG Package Size 60 |
11/01/2022 |
2539.79 |
29274.47 |
10/12/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/12/2019 |
Novartis |
0 |
1 |
None |
1.00 |
0.00 |
2020 |
24000.00 |
None |
The product was acquired from Novartis in the late stage development phase. It was brought to market the following year. As a result there was no WAC price at acquisition as the product was not on market at that time. We entered 1.00 for WAC at acquisition in order to submit the report. Recordati paid Novartis $390m for the acquisition of Signifor and in-development osilodrostat, which Recordati brought to market under the brand name Isturisa in 2020. |
| Rx0000363 |
Recordati Rare Diseases, inc. |
03/31/2022 |
55292012252 |
NeoProfen Inj (Ibuprofen lysine), 2 ml/vial, 3 vials |
01/05/2022 |
268.25 |
2950.77 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
03/31/2022 |
55292070255 |
Panhematin Inj 350 mg (Hemin for Injection), 48 ml/vial |
01/05/2022 |
775.20 |
9388.51 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
09/30/2022 |
55292013901 |
SIGNIFOR LAR Intra-muscular Suspension 10 mg - 1 Kit |
08/01/2022 |
584.10 |
15186.66 |
05/23/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/12/2019 |
Novartis |
None |
1 |
None |
12678.06 |
12308.80 |
2018 |
13058.40 |
None |
Note this product represents a repackaging of Signifor LAR under the 55292 Recordati labeler code. The "WAC at introduction" represents the WAC price when the product was first repackaged under the 55292 labeler code. The "year introduced" represents the year the product itself came to market. |
| Rx0000363 |
Recordati Rare Diseases, inc. |
09/30/2022 |
00078074881 |
Signifor LAR Intramuscular Suspension 10 mg - 1 Kit |
08/01/2022 |
584.10 |
15186.66 |
05/23/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/12/2019 |
Novartis |
None |
1 |
None |
12678.06 |
12308.80 |
2018 |
12308.00 |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
09/30/2022 |
55292014001 |
SIGNIFOR LAR Intra-muscular Suspension 20 mg - 1 Kit |
08/01/2022 |
584.10 |
15186.66 |
05/23/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/12/2019 |
Novartis |
None |
1 |
None |
12678.06 |
12308.80 |
2014 |
13058.40 |
None |
Note this product represents a repackaging of Signifor LAR under the 55292 Recordati labeler code. The "WAC at introduction" represents the WAC price when the product was first repackaged under the 55292 labeler code. The "year introduced" represents the year the product itself came to market. |
| Rx0000363 |
Recordati Rare Diseases, inc. |
09/30/2022 |
00078064181 |
Signifor LAR Intramuscular Suspension 20 mg - 1 Kit |
08/01/2022 |
584.10 |
15186.66 |
05/23/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/12/2019 |
Novartis |
None |
1 |
None |
12678.06 |
12308.80 |
2014 |
10769.23 |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
09/30/2022 |
55292014101 |
SIGNIFOR LAR Intra-muscular Suspension 30 mg - 1 Kit |
08/01/2022 |
584.10 |
15186.66 |
05/23/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/12/2019 |
Novartis |
None |
1 |
None |
12678.06 |
12308.80 |
2018 |
13058.40 |
None |
Note this product represents a repackaging of Signifor LAR under the 55292 Recordati labeler code. The "WAC at introduction" represents the WAC price when the product was first repackaged under the 55292 labeler code. The "year introduced" represents the year the product itself came to market. |
| Rx0000363 |
Recordati Rare Diseases, inc. |
09/30/2022 |
00078074181 |
Signifor LAR Intramuscular Suspension 30 mg - 1 Kit |
08/01/2022 |
584.10 |
15186.66 |
05/23/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/12/2019 |
Novartis |
None |
1 |
None |
12678.06 |
12308.80 |
2018 |
12308.00 |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
09/30/2022 |
55292014201 |
SIGNIFOR LAR Intra-muscular Suspension 40 mg - 1 Kit |
08/01/2022 |
584.10 |
15186.66 |
05/23/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/12/2019 |
Novartis |
None |
1 |
None |
12678.06 |
12308.80 |
2014 |
13058.40 |
None |
Note this product represents a repackaging of Signifor LAR under the 55292 Recordati labeler code. The "WAC at introduction" represents the WAC price when the product was first repackaged under the 55292 labeler code. The "year introduced" represents the year the product itself came to market. |
| Rx0000363 |
Recordati Rare Diseases, inc. |
09/30/2022 |
00078064281 |
Signifor LAR Intramuscular Suspension 40 mg - 1 Kit |
08/01/2022 |
584.10 |
15186.66 |
05/23/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/12/2019 |
Novartis |
None |
1 |
None |
12678.06 |
12308.80 |
2014 |
10769.23 |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
09/30/2022 |
55292014301 |
SIGNIFOR LAR Intra-muscular Suspension 60 mg - 1 Kit |
08/01/2022 |
584.10 |
15186.66 |
05/23/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/12/2019 |
Novartis |
None |
1 |
None |
12678.06 |
12308.80 |
2014 |
13058.40 |
None |
Note this product represents a repackaging of Signifor LAR under the 55292 Recordati labeler code. The "WAC at introduction" represents the WAC price when the product was first repackaged under the 55292 labeler code. The "year introduced" represents the year the product itself came to market. |
| Rx0000363 |
Recordati Rare Diseases, inc. |
09/30/2022 |
00078064381 |
Signifor LAR Intramuscular Suspension 60 mg - 1 Kit |
08/01/2022 |
584.10 |
15186.66 |
05/23/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/12/2019 |
Novartis |
None |
1 |
None |
12678.06 |
12308.80 |
2014 |
10769.23 |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
09/30/2022 |
00078063320 |
Signifor Subcutaneous Solution 0.3mg/1mL - 60 ampules - 1 Box |
08/01/2022 |
615.32 |
15998.29 |
12/14/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/12/2019 |
Novartis |
None |
1 |
None |
13546.42 |
13151.86 |
2012 |
14383.56 |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
09/30/2022 |
00078063420 |
Signifor Subcutaneous Solution 0.6mg/1mL - 60 ampules - 1 Box |
08/01/2022 |
615.32 |
15998.29 |
12/14/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/12/2019 |
Novartis |
None |
1 |
None |
13546.42 |
13151.86 |
2012 |
14383.56 |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
09/30/2022 |
00078063520 |
Signifor Subcutaneous Solution 0.9mg/1mL - 60 ampules - 1 Box |
08/01/2022 |
615.32 |
15998.29 |
12/14/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/12/2019 |
Novartis |
None |
1 |
None |
13546.42 |
13151.86 |
2012 |
14383.56 |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
03/31/2022 |
55292030401 |
Tranxene T-Tab 7.5 mg (Clorazepate dipotassium), 100 tabs/bottle |
01/05/2022 |
130.46 |
1435.04 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000239 |
Rigel Pharmaceuticals, Inc. |
06/30/2022 |
71332000101 |
Tavalisse 100 mg oral tablet 60 count |
04/25/2022 |
620.00 |
13020.00 |
07/27/2032 |
Single Source Drug |
None |
1 |
Rigel's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Rigel to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000239 |
Rigel Pharmaceuticals, Inc. |
06/30/2022 |
71332000201 |
Tavalisse 150 mg oral tablet 60 count |
04/25/2022 |
620.00 |
13020.00 |
07/27/2032 |
Single Source Drug |
None |
1 |
Rigel's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Rigel to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000321 |
R-Pharm US, LLC |
03/31/2022 |
70020191001 |
IXEMPRA Kit 15mg |
01/01/2022 |
33.15 |
1690.65 |
11/01/2025 |
Single Source Drug |
5100 |
None |
Increases in raw materials and manufacturing cost (since this is manufactured by third party. Additionally, we had increase cost from our 3PL for providing services. |
None |
None |
1 |
01/01/2016 |
BMS |
1080 |
None |
None |
1080.00 |
1080.00 |
2007 |
1080.00 |
None |
None |
| Rx0000321 |
R-Pharm US, LLC |
03/31/2022 |
70020191101 |
IXEMPRA Kit 45mg |
01/01/2022 |
99.45 |
5071.95 |
11/01/2025 |
Single Source Drug |
2670 |
None |
Increases in raw materials and manufacturing cost (since this is manufactured by third party. Additionally, we had increase cost from our 3PL for providing services. |
None |
None |
1 |
01/01/2016 |
BMS |
3241 |
None |
None |
3241.00 |
3241.00 |
2007 |
3241.00 |
None |
None |